Edition:
India

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

17.68CHF
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
CHF17.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,976
52-wk High
CHF74.00
52-wk Low
CHF16.50

Chart for

About

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF237.58
Shares Outstanding(Mil.): 6.29
Dividend: --
Yield (%): --

Financials

  SANN.S Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -6.40 -- --
ROI: -37.59 14.84 14.38
ROE: -55.62 16.34 16.07

BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy ‍​

* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Apr 2018

Swiss stocks - Factors to watch on March 20

ZURICH, March 20 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,841 points on Tuesday, according to premarket indications by bank Julius Baer .

20 Mar 2018

BRIEF-Santhera Pharmaceuticals FY ‍Net Result At CHF -51.5 Mln

* SANTHERA PHARMACEUTICALS - FY ‍NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION​

20 Mar 2018

Santhera's Raxone shows no efficacy benefit in MS study

ZURICH Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.

05 Mar 2018

BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​

* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​

05 Mar 2018

BRIEF-Santhera Completes Capital Increase To Settle Obtained License From Polyphor

* SANTHERA COMPLETES CAPITAL INCREASE TO SETTLE OBTAINED LICENSE FROM POLYPHOR

22 Feb 2018

BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor

* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

15 Feb 2018

BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD

* SANTHERA LAUNCHES U.S. EXPANDED ACCESS PROGRAM WITH IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

06 Feb 2018

BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million

* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE

29 Jan 2018

BRIEF-Santhera: Negative CHMP Opinion On Appeal For Authorization Of Raxone

* SANTHERA RECEIVES NEGATIVE CHMP OPINION ON APPEAL FOR AUTHORIZATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

26 Jan 2018

Earnings vs. Estimates